Click Here to return To Results

 

Interim Results from the CATNON trial (EORTC study 260-53-22054) of treatment with Concurrent and Adjuvant Temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomized, open-label intergroup study Lancet 390:1645-1653, Van Den Bent, M.J.,et al, 2017 See this aricle in Pubmed Article Abstract Adjuvant temozolomide chemotherapy was associated with a significant survival benefit in patients with newly diagnosed non-co-deleted anaplastic glioma. Further analysis of the role of concurrent temozolomide treatment and molecular factors is needed.

Related Tags

(click to filter results - removes previous filter) chemotherapy,CNS treatment and complications with efficacy glioblastoma multiforme(astrocytoma Gr.III) glioma neoplasm,primary intracerebral neoplasm,primary of CNS neoplasm,primary of CNS-survival neoplasm,primary of CNS-treatment of practice guidelines prognosis radiation therapy,CNS treatment and complications with temozolomide treatment of neurologic disorder

Click Here to return To Results